2022 Fiscal Year Final Research Report
Development of novel mucosal vaccines using reovirus vectors
| Project/Area Number |
21K19379
|
|---|
| Research Category |
Grant-in-Aid for Challenging Research (Exploratory)
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Medium-sized Section 49:Pathology, infection/immunology, and related fields
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2021-07-09 – 2023-03-31
|
| Keywords | レオウイルス / ワクチン |
|---|
| Outline of Final Research Achievements |
The aim of this project is to develop mucosal vaccines against the novel coronavirus (SARS-CoV-2), which has had a significant impact on the global economy, and norovirus (NV), which causes acute gastroenteritis, using mammalian reoviruses (MRVs). We generated recombinant MRV by inserting the receptor-binding domain of the SARS-CoV-2 spike protein, fused with a 2A sequence, into the MRV S1 gene segment. For the generation of recombinant MRV expressing the NV protein, we inserted the NV VP1 gene within the MRV S gene segment. The recombinant viruses were analyzed in vitro and in vivo, providing valuable insights for the further development of MRV vectors.
|
| Free Research Field |
ウイルス学
|
| Academic Significance and Societal Importance of the Research Achievements |
哺乳類レオウイルス（MRV）は病原性が極めて低く、経鼻、経口投与により粘膜免疫を誘導できることから優れた粘膜ワクチンベクター候補と考えられる。本研究ではヒトノロウイルスおよび新型コロナウイルスのワクチン開発を目的として、各種ウイルス抗原を発現する組換えMRVの作製を行った。in vivoにおける解析結果から、克服すべき課題も見つかり、引き続き、開発研究を進める必要はあるものの、これらの成果は様々な呼吸器・消化器感染症に対するワクチン開発にも応用可能と考えられ、社会的意義も高い。
|
